Southcoast Health

Active Clinical Trials

- **TUG Trial - Predicting tolerance of adjuvant or neoadjuvant chemotherapy using the "Timed Up and Go" test.**
  Investigator initiated study
  The primary outcome to be measured is the time of the actual TUG test. Each patient will have a score recorded corresponding to how many seconds it takes to complete the test. In addition, cancer specific information will be recorded as follows: type of cancer, stage, type of initial local management and type of chemotherapy, dose and course of radiation.
  Sonia Seng, MD Oncologist
  Protocol # SC-0111
- **Phase III Protocol J2J-MC-JZLH EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast.**
  Eli-Lilly
  To evaluate the efficacy of imlunestrant vs Standard of care adjuvant ET, in patients who have received 2 to 5 years of standard ET for ER+,HER2- EBC with an increased risk of recurrence.
  Sonia Seng, MD Oncologist
  NCT # 05514054
- **eVOLVE-HNSCC - A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy**
  The aim of this study is to assess the efficacy and safety of volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) after receiving definitive concurrent chemoradiotherapy (cCRT)
  Sonia Seng, MD Oncologist
  NCT # 06129864
- **HALO - New Non-Interventional Post Market Authorization Study for Multiple Myeloma patients.**
  Janssen
  Describe the baseline and treatment characteristics of participants with MM receiving the first 3 administrations of daratumumab IV/SC and identify the risk factors for incidents Grade 3 and 4.
  Sonia Seng, MD Oncologist
  Protocol # 54767414NAP4001
- **A randomized, phase 3, open-label study to evaluate SGN-B6A compared with docetaxel in adult subjects with previously treated non-small cell lung cancer.**
  Pfizer
  To compare the overall survival (OS) between the experimental arm (sigvotatug vedotin) and control arm (docetaxel) in all participants and in the IB6-high subgroup.
  Sonia Seng, MD Oncologist
  NCT # 06012435
- **ARIES - A Biobank Registry Platform Study in Oncology**
  TEMPUS/TIME platform
  Blood and left-over clinical tissue samples will be collected prospectively along with combined clinical and molecular health information from patients with cancer at multiple academic and community medical centers (each an "institution") to help further understanding of the nature of treatment response across tumor types.
  Sonia Seng, MD Oncologist
  Protocol # TP-CA-007

- **Engaging Community Practices to Improve the Pathway for Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma**

  Premier Healthcare Solutions

  This project seeks to address real-world barriers to guideline- and evidence-based care, ensure appropriate treatment decision-making, and align patient-provider goals for care in the community setting among hematology/ oncology teams caring for patients with RRMM.

  Sonia Seng, MD Oncologist

  Protocol # PQH_MM_2024

- **Biospecimen Trials with Precision – ONC53**

  PRECISION

  This is a targeted enrollment program open to subjects with metastatic breast cancer or triple negative breast cancer. The objective of this project is to further understand the behavior of CTC in Breast Cancer to develop more efficient targeted therapeutic treatments.

  Sonia Seng, MD Oncologist

  Protocol # PFM064

- **TEMPUS/TIME trial platform**

  This platform gives Southcoast Center for Cancer Care the opportunity to open trials in a rapid fashion to offer our community the most advance care at our site. It contains more than 25 studies that has been tailored to our patients to give them the opportunity to be treated based on their needs.

  Sonia Seng, MD Oncologist

- **Phase 1/2a, A study on Enfortumab Vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer.**

  Pfizer

  Study EV-103 was designed to evaluate the safety, antitumor activity, and pharmacokinetics of enfortumab vedotin as monotherapy or in combination with pembrolizumab and/or chemotherapy in patients with locally advanced or metastatic urothelial cancer or muscle invasive bladder cancer.

  Sonia Seng, MD Oncologist

  NCT # 03288545

- **SERENA 6 - Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC with Detectable ESR1m before Progression.**

  AstraZeneca

  Demonstrate superiority of AZD9833 plus CDK4/6 inhibitor relative to AI plus CDK4/6 inhibitor by assessment of PFS in the final analysis set.

  Sonia Seng, MD Oncologist

  NCT # 04711252

- **DAROL - Darolutamide observational study in non-metastatic castration-resistant prostate cancer patients.**

  Bayer

  The purpose of this study is to describe, under real-world conditions, the safety and effectiveness of darolutamide in patients with non-metastatic castration-resistant prostate cancer for whom a decision to treat with darolutamide has been made before enrollment.

  Sonia Seng, MD Oncologist

  Protocol # 20590

- **SKYSCRAPER-03 - Phase III Atezolizumab and Tiragolumab compared with Durvalumab in participants with locally advanced, Unresectable stage III NSCLC.**

  Genentech

  To evaluate the efficacy of tiragolumab plus atezolizumab compared with durvalumab in the final analysis set.

  Sonia Seng, MD Oncologist

  NCT # 04513925

Southcoast Health

For more information about trials, you can look up at Clincialtrials.gov.

https://clinicaltrials.gov/